ZA959388B - Compositions comprising carbazoles and cyclodextrins - Google Patents
Compositions comprising carbazoles and cyclodextrinsInfo
- Publication number
- ZA959388B ZA959388B ZA959388A ZA959388A ZA959388B ZA 959388 B ZA959388 B ZA 959388B ZA 959388 A ZA959388 A ZA 959388A ZA 959388 A ZA959388 A ZA 959388A ZA 959388 B ZA959388 B ZA 959388B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbazoles
- cyclodextrins
- compositions
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94203242 | 1994-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA959388B true ZA959388B (en) | 1997-05-06 |
Family
ID=8217355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA959388A ZA959388B (en) | 1994-11-07 | 1995-11-06 | Compositions comprising carbazoles and cyclodextrins |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU3846395A (tr) |
IL (1) | IL115885A0 (tr) |
TR (1) | TR199501376A2 (tr) |
WO (1) | WO1996014090A1 (tr) |
ZA (1) | ZA959388B (tr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ330596A (en) | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
CN100572363C (zh) | 2000-11-17 | 2009-12-23 | 武田药品工业株式会社 | 咪唑衍生物、其制备方法及其用途 |
US6960586B2 (en) | 2000-11-20 | 2005-11-01 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, process for their preparation and their use |
CA2431171A1 (en) | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
GEP20156250B (en) | 2009-06-26 | 2015-02-25 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
BR112012009262A2 (pt) * | 2009-10-23 | 2019-09-24 | Health Research Inc | ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo |
JP5998137B2 (ja) | 2010-08-04 | 2016-09-28 | ペルフィキュア ファーマシューティカルズ,インコーポレイテッド | 前立腺癌を処置するための併用療法 |
EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
ES2656218T3 (es) | 2011-04-28 | 2018-02-26 | Novartis Ag | Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa |
WO2014158875A1 (en) | 2013-03-14 | 2014-10-02 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
US10093620B2 (en) | 2014-09-12 | 2018-10-09 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
EP3528799A1 (en) | 2016-10-24 | 2019-08-28 | Pellficure Pharmaceuticals, Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
-
1995
- 1995-10-31 WO PCT/EP1995/004295 patent/WO1996014090A1/en active Application Filing
- 1995-10-31 AU AU38463/95A patent/AU3846395A/en not_active Abandoned
- 1995-11-06 IL IL11588595A patent/IL115885A0/xx unknown
- 1995-11-06 ZA ZA959388A patent/ZA959388B/xx unknown
- 1995-11-07 TR TR95/01376A patent/TR199501376A2/tr unknown
Also Published As
Publication number | Publication date |
---|---|
AU3846395A (en) | 1996-05-31 |
WO1996014090A1 (en) | 1996-05-17 |
TR199501376A2 (tr) | 1996-06-21 |
IL115885A0 (en) | 1996-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL314956A1 (en) | Siclicium-sodium-calcium glass compositions and their application | |
IL115891A0 (en) | Hemorrhoidial compositions and their use | |
PL327659A1 (en) | Disinfecting compositions and surface disinfecting methods | |
GB9616411D0 (en) | Shampoo compositions and method | |
PL332699A1 (en) | Immunomodulation methods and compositions | |
GB9525977D0 (en) | Perfluoroelastomeric compositions and methods | |
IL126546A (en) | Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin | |
AU3641597A (en) | Methods and compositions comprising r-ibuprofen | |
GB9525812D0 (en) | Composition and use | |
AU2972597A (en) | Compositions and uses thereof | |
ZA959388B (en) | Compositions comprising carbazoles and cyclodextrins | |
PL331423A1 (en) | Muporocin and chlorohexidrin containing compositions | |
ZA9510792B (en) | Polymerization compounds and compositions | |
GB9624501D0 (en) | Insecticial compositions and method | |
HUP9802997A3 (en) | Antisudorific and/or deodorant compositions | |
US5478356B1 (en) | Cyanoimides and compositions useful for bleaching | |
AU3674595A (en) | Antianemic agent containing iron and difructose | |
PL331523A1 (en) | Azolotrizines and azolopyrimidines | |
GB9415453D0 (en) | Anti perspirant compositions | |
AUPO982097A0 (en) | Methods and compositions for use therein | |
AU691690B2 (en) | Acrolein-releasing composition and use thereof | |
HUP9900068A3 (en) | Fuse-switch and/or fuse-disconnector | |
AU1468797A (en) | Ghrh-rp compositions and methods | |
AU3227295A (en) | Oil treatment and compositions therefor | |
AU2646795A (en) | Detergent compositions comprising oleoyl sarcosinate and enzymes |